title: Seahorse-derived peptide suppresses invasive migration of HT1080 fibrosarcoma cells by competing with intracellular α-enolase for plasminogen binding and inhibiting uPA-mediated activation of plasminogen.
abstract: α-Enolase is a glycolytic enzyme and a surface receptor for plasminogen. α-Enolase-bound plasminogen promotes tumor cell invasion and cancer metastasis by activating plasmin and consequently degrading the extracellular matrix degradation. Therefore, α-enolase and plasminogen are novel targets for cancer therapy. We found that the amino acid sequence of a peptide purified from enzymatic hydrolysates of seahorse has striking similarities to that of α-enolase. In this study, we report that this peptide competes with cellular α-enolase for plasminogen binding and suppresses urokinase plasminogen activator (uPA)-mediated activation of plasminogen, which results in decreased invasive migration of HT1080 fibrosarcoma cells. In addition, the peptide treatment decreased the expression levels of uPA compared to that of untreated controls. These results provide new insight into the mechanism by which the seahorse-derived peptide suppresses invasive properties of human cancer cells. Our findings suggest that this peptide could emerge as a potential therapeutic agent for cancer.
authors.affiliation: Department of Food Science and Technology, Kunsan National University, Kunsan 573-701, Korea.
authors.forename: Yong-Tae
authors.initials: YT
authors.lastname: Kim
authors.affiliation: Department of Chemistry, Pukyong National University, Busan 608-737, Korea.
authors.forename: Se-kwon
authors.initials: SK
authors.lastname: Kim
authors.affiliation: Department of Marine Life Sciences, Jeju National University, Jeju 690-756, Korea.
authors.forename: You-Jin
authors.initials: YJ
authors.lastname: Jeon
authors.affiliation: Department of Chemistry, Pukyong National University, Busan 608-737, Korea.
authors.forename: Sun Joo
authors.initials: SJ
authors.lastname: Park
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects*; D004800:Enzymes, Immobilized / Q000737:chemistry / Q000378:metabolism; D005354:Fibrosarcoma / Q000378:metabolism / Q000473:pathology; D006801:Humans; D047468:Immunoprecipitation; D010455:Peptides / Q000138:chemical synthesis / Q000302:isolation & purification / Q000494:pharmacology*; D010751:Phosphopyruvate Hydratase / Q000737:chemistry / Q000378:metabolism*; D010958:Plasminogen / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D011485:Protein Binding; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000378:metabolism; D023701:Smegmamorpha / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
chemical_list: D004800:Enzymes, Immobilized; D010455:Peptides; D034741:RNA, Small Interfering; D010958:Plasminogen; D014568:Urokinase-Type Plasminogen Activator; D010751:Phosphopyruvate Hydratase